Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference32 articles.
1. Treatment of non-Hodgkin lymphoma;Hauke;Curr. Opin. Oncol.,2000
2. Improving second-line therapy in aggressive non-Hodgkin’s lymphoma;Gisselbrecht;Semin. Oncol.,2004
3. Defining the role of mTOR in cancer;Guertin;Cancer Cell,2007
4. Targeting the phosphoinositide 3-kinase pathway in cancer;Liu;Nat. Rev. Drug Discov.,2009
5. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations;LoPiccolo;Drug Resist. Updates,2008
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins;Cancers;2022-03-27
2. Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non‐Hodgkin lymphoma;Cancer Medicine;2019-06-20
3. Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer;Journal of Cancer;2018
4. Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles;Cancer Nanotechnology;2017-10-26
5. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies;Cancer Chemotherapy and Pharmacology;2017-06-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3